Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

De Marinis, Yang LU ; Sunnerhagen, Torgny LU orcid ; Bompada, Pradeep ; Bläckberg, Anna LU ; Yang, Runtao ; Svensson, Joel LU ; Ekström, Ola LU ; Eriksson, Karl Fredrik LU ; Hansson, Ola LU orcid and Groop, Leif LU , et al. (2020) In Infection Ecology and Epidemiology 10(1).
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks disease duration; and 91% in... (More)

The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks disease duration; and 91% in hospitalized patients with >2 weeks disease duration. We also compared different blood sample types and suggest a higher sensitivity by serum/plasma over whole blood. Test specificity was determined to be 97% on 69 sera/plasma samples collected between 2016-2018. Our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our results support that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
antibody test, COVID-19, disease severity and duration, IgM and IgG, SARS-CoV-2, serology assessment
in
Infection Ecology and Epidemiology
volume
10
issue
1
article number
1821513
publisher
Taylor & Francis
external identifiers
  • scopus:85091301104
  • pmid:33062217
ISSN
2000-8686
DOI
10.1080/20008686.2020.1821513
project
Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test
language
English
LU publication?
yes
id
7881faa4-20c3-47dc-896b-90bbaef63760
date added to LUP
2020-11-03 11:58:30
date last changed
2024-06-27 00:17:36
@article{7881faa4-20c3-47dc-896b-90bbaef63760,
  abstract     = {{<p>The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with &lt;2 weeks from disease onset; 85% in non-hospitalized patients with &gt;2 weeks disease duration; and 91% in hospitalized patients with &gt;2 weeks disease duration. We also compared different blood sample types and suggest a higher sensitivity by serum/plasma over whole blood. Test specificity was determined to be 97% on 69 sera/plasma samples collected between 2016-2018. Our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our results support that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.</p>}},
  author       = {{De Marinis, Yang and Sunnerhagen, Torgny and Bompada, Pradeep and Bläckberg, Anna and Yang, Runtao and Svensson, Joel and Ekström, Ola and Eriksson, Karl Fredrik and Hansson, Ola and Groop, Leif and Gonçalves, Isabel and Rasmussen, Magnus}},
  issn         = {{2000-8686}},
  keywords     = {{antibody test; COVID-19; disease severity and duration; IgM and IgG; SARS-CoV-2; serology assessment}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Taylor & Francis}},
  series       = {{Infection Ecology and Epidemiology}},
  title        = {{Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test}},
  url          = {{https://lup.lub.lu.se/search/files/119180326/Serology_assessment_of_antibody_response_to_SARS_CoV_2_in_patients_with_COVID_19_by_rapid_IgM_IgG_antibody_test.pdf}},
  doi          = {{10.1080/20008686.2020.1821513}},
  volume       = {{10}},
  year         = {{2020}},
}